• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·2160.HK
Share

MicroPort CardioFlow Medtech Corporation Stocks

HK$ 1.28Last Updated 17.09.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

HK$ 80.24M

HK$ 1.28
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.10.2026 12:53

Anthropic's revenue surge will help its IPO, but is unlikely to save the entire AI sector, experts say

15.10.2026 12:37

"They Started Catching Up Late, but Quickly": Movchan's Group Guide to Investing in Kazakhstan

15.10.2026 12:21

Freedom recommended buying shares in Marriott, Hilton, and other hotel chains. What's the opportunity here?

15.10.2026 11:07

The world's leading chipmaker posted record profits for the sixth consecutive time

15.10.2026 10:26

Morning Highlights: Global Stocks Fall; Anthropic Reports Revenue Growth Ahead of Its IPO

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026